LitAlert ~~ GeneLit.com

    • Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    • Ma D, Jiang YZ, Xiao Y, Xie MD, Zhao S, Jin X, Xu XE, Shao ZM
    • Cancer. 2020 May 8. doi: 10.1002/cncr.32922. [Epub ahead of print]
    • Clustering of known low and moderate risk alleles rather than a novel recessive high-risk gene in non-BRCA1/2 sib trios affected with breast cancer.
    • Hilbers FS, Hof PJ, Meijers CM, Mei H, Michailidou K, Dennis J, Hogervorst FBL, Nederlof PM, van Asperen CJ, Devilee P.
    • Int J Cancer. 2020 May 7. doi: 10.1002/ijc.33039. [Epub ahead of print]
    • Germline RBBP8 variants associated with early-onset breast cancer compromise replication fork stability.
    • Zarrizi R, Higgs MR, Voßgröne K, Rossing M, Bertelsen B, Bose M, Kousholt AN, Rösner HI, Ejlertsen B, Stewart GS, Nielsen FC, Sørensen C.
    • J Clin Invest. 2020 May 7. pii: 127521. doi: 10.1172/JCI127521. [Epub ahead of print]
    • Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation.
    • Lugo Santiago N, Smith E, Cox M, Wan CS, Tchabo NE, Awowole I, Broach V, Chi, DS.
    • Obstet Gynecol. 2020 May 7. doi: 10.1097/AOG.0000000000003864. [Epub ahead of print]
    • Case report
    • The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer.
    • van der Merwe NC, Oosthuizen J, Theron M, Chong G, Foulkes WD.
    • BMC Cancer. 2020 May 6;20(1):391. doi: 10.1186/s12885-020-06917-y.
    • Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.
    • Tennen RI, Laskey SB, Koelsch BL, McIntyre MH, Tung JY.
    • Sci Rep. 2020 May 6;10(1):7669. doi: 10.1038/s41598-020-63466-x.
    • FDA approves niraparib for first-line maintenance of advanced ovarian cancer.
    • [No author given.]
    • U.S. Food & Drug Administration. Drug Approvals and Databases. 2020 Apr 29.

    Research review: Study: New FDA approval for maintenance therapy in ovarian cancer. (FORCE. XRAYS.)

    • Mucinous Histology, BRCA1/2 Mutations, and Elevated Tumor Mutational Burden in Colorectal Cancer.
    • Harpaz N, Gatt YE, Granit RZ, Fruchtman H, Hubert A, Grinshpun A.
    • J Oncol. 2020 Apr 25;2020:6421205. doi: 10.1155/2020/6421205. eCollection 2020.
    • Psammoma bodies in Papanicolaou tests and associated factors to predict an underlying malignancy: a clinicopathological analysis of 10 cases.
    • Ersoy E, Kashikar RM.
    • J Am Soc Cytopathol. 2020 Apr 11. pii: S2213-2945(20)30059-4. doi: 10.1016/j.jasc.2020.04.002. [Epub ahead of print]